Little information has been published concerning the severity of pain experienced by bone marrow donors or the use of local analgesia following bone marrow harvesting procedures. The aims of this study were to assess duration and severity of pain experienced by bone marrow donors and the effectiveness of bupivacaine as a local analgesic agent following bone marrow harvest. During a single blinded randomised study of 24 bone marrow donors, 10 ml of 0.5% bupivacaine was infiltrated either into the right or left posterior iliac crest of the donor immediately following bone marrow harvest. Donors were requested to record the level of pain experienced at the right and left harvest sites on a pain rating score sheet (0-10) at time intervals of 4, 8, 12, 24, 48 and 72 h following harvest. A significant reduction in pain was experienced at the harvest site infiltrated with bupivacaine when compared with the control site during the first 3 days post-harvest. It is recommended that bupivacaine be infiltrated routinely into the harvest sites of all bone marrow donors to reduce the pain experienced in the 3 days following harvest. Keywords: bupivacaine; bone marrow transplantation; analgesia; donor morbidity While bone marrow harvesting is a safe procedure, 1,2 some donors experience pain at the bone marrow harvest site that may require prolonged hospital admission for narcotic analgesia. Few studies exist which have looked at morbidity following bone marrow harvesting.
While bone marrow harvesting is a safe procedure, 1,2 some donors experience pain at the bone marrow harvest site that may require prolonged hospital admission for narcotic analgesia. Few studies exist which have looked at morbidity following bone marrow harvesting. [1] [2] [3] [4] Routinely, bone marrow harvesting is performed under general or less frequently spinal anaesthesia with simple analgesics used for post-operative pain management. A study by Hill et al 1 found that 80% of donors required medication with paracetamol and codeine for an average of 3.3 days post-bone marrow harvest and ranging from 1 to 13 days. However, pain intensity ratings and the number of days of medication indicated that paracetamol and codeine did not provide complete relief of pain post-harvest and further optimisation of pain management following bone marrow harvest was required. The aims of this study were to assess quantitatively severity of pain experienced by bone marrow donors Correspondence: Dr CJ Hutchins, BMT Unit (Ward 9E), Royal Brisbane Hospital, Herston, Brisbane 4029, Australia Received 17 August 1998; accepted 10 December 1998 using a pain rating score and the efficacy of bupivacaine infiltration into the bone marrow harvest site for postoperative analgesia.
Methods
Consecutive autologous or allogeneic bone marrow donors scheduled to have an elective bone marrow harvest at the Royal Brisbane Hospital were asked to participate in this single blinded randomised study. After informed consent was obtained, each donor was randomised to have bupivacaine infiltrated into either the right or left posterior iliac crest immediately following bone marrow harvest. All donors received general anaesthesia with specific agents and techniques used at the discretion of the treating anaesthetist. While the donor remained under general anaesthesia at the completion of the bone marrow harvest procedure, 10 ml of 0.5% bupivacaine was infiltrated on to the periosteum of the randomised side. Post-operatively, the donors were required to complete a score sheet rating pain from 0 (no pain) to 10 (worst imaginable pain) reflecting the pain experienced in the left and right harvest sites at time intervals of 4, 8, 12, 24, 48 and 72 h following the bone marrow harvest. In addition, donors were requested to report pain that persisted beyond 3 days. Donors were not informed of the result of randomisation. Pain experienced by donors in control and bupivacaine infiltrated sites at time intervals post-harvest was analysed using a paired t-test (two-tailed). An interim analysis was performed after 24 patients had participated in the study.
Results
Twenty-five consecutive bone marrow donors were approached for inclusion in the study of local analgesia with bupivacaine. Informed consent was obtained from 24 of the 25 donors. This group included donors for four autologous and 20 allogeneic bone marrow transplants. There were 15 female and nine male donors with an average age of 35 years. Randomisation resulted in bupivacaine infiltration on the left posterior iliac crest in 13 cases and on the right in 11 cases. Bone marrow was harvested from the site randomised for bupivacaine infiltration by a consultant on 11 occasions, a registrar on 11 occasions and a resident medical officer on two occasions.
The magnitude of pain reported by individual donors using the pain rating scale ranged from 0 to 8 on both the control and treatment sides. Pain scores experienced by individual donors did not correlate with the volume of bone marrow harvested. The mean pain score experienced by 24 donors in the control and bupivacaine infiltrated harvest sites at various time intervals post-bone marrow harvest is presented in Table 1 . Significantly lower mean pain scores were reported for the side infiltrated with bupivacaine at all time intervals investigated. The study was discontinued after analysis of these interim results and bupivacaine infiltration of bone marrow harvest sites performed routinely.
At 4 h after bone marrow harvest, six donors (25%) reported no pain on the treatment side. However, only two of these six donors (8%) reported no pain on the control side. Pain that persisted for longer than 3 days was reported by six donors (25%) on the control side and only one donor (4%) on the bupivacaine infiltrated side.
A higher pain score was reported by one donor on the bupivacaine infiltrated side as opposed to the control side at all time intervals between 12 to 72 h. A higher pain score on the treatment side (pain score of 2 vs 1) was reported at one time interval (12 h) by another donor. Two donors reported no difference in pain experienced at either side at any time interval.
Analysis of the average difference in the pain rating score of the control and bupivacaine infiltrated sides per individual for each time interval indicates that the difference in pain experienced by each donor between the bupivacaine infiltrated side and the control side becomes less marked with time post-procedure. There were no complications directly related to use of bupivacaine in this study.
Discussion
While concerns regarding donor morbidity have been expressed in the literature, 1,2,5,6 the severity of pain experienced has not been formally assessed. This prospective, single blinded, randomised study of 24 consecutive bone marrow donors shows that the local pain experienced by donors following bone marrow harvesting is significantly improved by bupivacaine infiltration into the harvest site at the completion of the procedure.
This has been demonstrated quantitatively using a pain rating score. Donors experienced significantly less pain at the site of bone marrow harvest after local anaesthesia with bupivacaine. Furthermore, the average individual difference Table 1 Mean pain score at various time intervals post-bone marrow harvest in the pain score between bupivacaine infiltrated and control sides demonstrated the effect of bupivacaine but this effect was reduced with time post-harvest. With both treatment and control arms occurring in the one donor, interindividual differences in assessment of pain score together with the possible influence of variables such as volume or cell number harvested and the duration or difficulty of harvest are negated. Individual variation in pain experienced is demonstrated by the range of the pain score (range: 0-8) experienced on the control side.
In the absence of bupivacaine, pain may persist for more than 3 days in up to 25% of cases. This also suggests that bupivacaine provided significant analgesia effective for at least 3 days. Bupivacaine is an amide local anaesthetic agent with a long duration of activity (half life, 277 Ϯ 34 min) and a relatively safe toxicity profile. Known adverse effects of bupivacaine include both minor and major neurological and cardiovascular disturbances. These complications are extremely rare when the recommended maximum single dose of 2 mg/kg is not exceeded. A total dose of 50 mg bupivacaine was used for this study during which statistically significant analgesia was observed. Hence, increasing the dose to cover the harvest sites at both right and left posterior iliac crests is unlikely to exceed the recommended maximum dose of bupivacaine for adult bone marrow donors.
Studies using bupivacaine infiltration for post-operative analgesia in other surgical settings [7] [8] [9] [10] have variable results, with bupivacaine showing either no advantage 7, 8 or a statistically significant improvement in pain control.
9,10 Todd and Reed 10 used bupivacaine infiltration into iliac bone graft donor sites. This most closely simulates the setting of bone marrow harvest. Pain reduction was achieved for the first 24 h, but only achieved significance during the first 4 h. This is in contrast with this study during which significant pain reduction was seen up to 72 h post-harvest. Jebeles et al 9 used bupivacaine infiltration into tonsillectomy and adenoidectomy sites and showed significant pain reduction at 5 days. This also demonstrates a prolonged analgesic effect of bupivacaine despite its half-life of only 277 min.
In conclusion, it is recommended that all bone marrow donors receive bupivacaine infiltrated into the bone marrow harvest sites to improve post-operative analgesia. The technique is safe, simple, inexpensive and highly effective. Reduced donor morbidity is of utmost significance with the increasing use of volunteer unrelated bone marrow donors.
